Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 202

Results For "ET"

10720 News Found

AstraZeneca and Scorpian Therapeutics partner to target novel cancer treatments
Biotech | January 14, 2022

AstraZeneca and Scorpian Therapeutics partner to target novel cancer treatments

The new collaboration focuses on a class of proteins called transcription factors, which control gene expression and can regulate important cellular processes including cell growth and survival


Metropolis Healthcare opens MedEngage Scholarship programme
News | January 13, 2022

Metropolis Healthcare opens MedEngage Scholarship programme

The last date to apply for this program is 18th January 2022


BioGenex RT-PCR Kit detects all Covid variants in half the time
Medical Device | January 13, 2022

BioGenex RT-PCR Kit detects all Covid variants in half the time

This test analyses samples in VTM directly without the need for RNA extraction step


AliveCor’ KardiaMobile gets NICE approval to detect irregular heart rhythm symptons
Medical Device | January 13, 2022

AliveCor’ KardiaMobile gets NICE approval to detect irregular heart rhythm symptons

KardiaMobile is the first personal ECG to be recommended by NICE for use within the National Health Service (NHS) in England and Wales


Marksons Pharma receive final US. FDA approval for Cetirizine Hydrochloride tablets
Drug Approval | January 12, 2022

Marksons Pharma receive final US. FDA approval for Cetirizine Hydrochloride tablets

The product will be marketed under store brand labels and is comparable to the brand Zyrtec


Alkem Labs to launch treatment for Diabetic Foot Ulcer
News | January 12, 2022

Alkem Labs to launch treatment for Diabetic Foot Ulcer

This advanced technology for Diabetic Foot Ulcer (DFU), management has a high scope of preventing amputations in diabetic patients. It has no definitive treatment in India. This technology will be available at affordable rates


Veristat supported marketing applications for 12 % of all FDA Novel Drug Approvals in 2021
News | January 12, 2022

Veristat supported marketing applications for 12 % of all FDA Novel Drug Approvals in 2021

This surpasses the number of approvals supported in 2020


We achieved  40% revenue growth in 2021 : Gaurav Kaushik, MD & CEO, Meteoric Biopharmaceuticals
Interviews | January 11, 2022

We achieved 40% revenue growth in 2021 : Gaurav Kaushik, MD & CEO, Meteoric Biopharmaceuticals

The biopharmaceutical market has been on a growth curve. India is number three in the Asia Pacific market. Gaurav Kaushik, MD & Director & CEO, Meteoric Biopharmaceuticals shares a perspective on the industry


Aurobindo’s CuraTeQ and Orion expand licencing deal in select European markets
News | January 11, 2022

Aurobindo’s CuraTeQ and Orion expand licencing deal in select European markets

CuraTeQ and Orion had entered into a licensing agreement, granting marketing and distribution rights for CuraTeQ’s biosimilar products under development in the Nordic states, Austria, Hungary and Slovenia


We achieved 40% revenue growth in 2021: Gaurav Kaushik, MD & CEO, Meteoric Biopharmaceuticals
interviews | January 10, 2022

We achieved 40% revenue growth in 2021: Gaurav Kaushik, MD & CEO, Meteoric Biopharmaceuticals

The biopharmaceutical market has been on a growth curve. India is number three in the Asia Pacific market. Gaurav Kaushik, MD & CEO, Meteoric Biopharmaceuticals shares a perspective on the industry